Home » GNW-Adhoc: iTeos Presents Preclinical Data on EOS-984 – the First-in-Class Anti-ENT1 Product – at the 2024 Annual Meeting of the American… | 03/05/24

GNW-Adhoc: iTeos Presents Preclinical Data on EOS-984 – the First-in-Class Anti-ENT1 Product – at the 2024 Annual Meeting of the American… | 03/05/24

by admin
GNW-Adhoc: iTeos Presents Preclinical Data on EOS-984 – the First-in-Class Anti-ENT1 Product – at the 2024 Annual Meeting of the American… |  03/05/24

^ WATERTOWN, Massachusetts, and GOSSELIES, Belgium, March 05, 2024 (GLOBE

NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), ein biopharmazeutisches

Clinical research company pioneering the

Research and development of a new generation of immuno-oncology

provides therapeutics for patients has a poster presentation today

announced preclinical data on EOS-984, the first small molecule

Antagonist of its class, which relies on the equilibrative nucleoside transporter 1

(ENT1). The presentation will take place at the annual meeting of the American

Association for Cancer Research (AACR), die vom 5. bis 10. April 2024 in San

Diego, California.

Details about the poster presentation

Abstract 734,?Inhibition of equilibrative nucleoside transporter 1 relieves

intracellular adenosine-mediated immune suppression” (Hemmung des Equilibrativen

Nucleoside transporter 1 alleviates intracellular adenosine-mediated


* Sitzung: Experimental and Molecular Therapeutics: Tumor Microenvironment

(Experimental and Molecular Therapeutics: Tumor Microenvironment)

* Date and Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT

* Ort: Poster Section 29

Über iTeos Therapeutics, Inc.

iTeos Therapeutics is a biopharmaceutical company in the field of

clinical research, pioneering research and development

a new generation of immuno-oncology therapeutics for patients

performs. Based on a deep understanding of tumor immunology and

iTeos Therapeutics is developing new immunosuppressive signaling pathways

Product candidates that have the potential to enhance the immune response against cancer

to restore. The company’s innovative pipeline includes three

Clinical phase programs based on novel, validated

Target immuno-oncological signaling pathways and with optimized pharmacological ones

Features developed for improved clinical outcomes include

the TIGIT/CD226 axis and the adenosine signaling pathway. iTeos Therapeutics has its

Headquarters in Watertown, MA and a research center in Gosselies, Belgium.

About EOS-984

See also  Conte says the Meloni government helps tax evaders and corrupt people

EOS-984 is the first small molecule drug in its class targeting the

Equilibrative nucleoside transporter 1 (ENT1) is aimed at immunosuppressive

Effect of adenosine to inhibit and proliferation of immune cells

to restore. The therapeutic candidate has the potential to be strong

to completely reverse the immunosuppressive effect of adenosine on T and B cells

and is in Phase I development.

Publication of information on the Internet

iTeos Therapeutics routinely publishes information intended for investors

could be important in the “Investors” section of his website

at www.iteostherapeutics.com. The company encourages investors and

potential investors to visit the website regularly for important information

Get information about iTeos Therapeutics.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that

are not based exclusively on historical facts, are future-oriented

Testify. Words like?believe”,?anticipate”,?plan”,?expect”,?become”,

“can”, “intend”, “prepare”, “see”, “potential”, “possible” and

Similar expressions are intended to identify forward-looking statements. To this

Forward-looking statements include statements about potential benefits

of product candidates in the Company’s pipeline, including EOS-984.

These forward-looking statements involve risks and uncertainties

connected, many of which are outside the control of iTeos. The

actual results may vary due to these risks and uncertainties

differ materially from those indicated in these forward-looking statements or

implied results differ. The known risk factors include:

following: iTeos could be due to challenges and uncertainties

with product research and development as well as the production of biologics

associated with facing unforeseen costs or cash

output faster or slower than currently expected; the success of preclinical

Tests and early clinical trials do not ensure later clinical trials

See also  Five departments in emergency over the weekend in Colombia

Studies will be successful, and early results from a clinical trial

do not necessarily predict the final results; the data for

our product candidates may not be sufficient to meet regulatory requirements

To obtain approval for later phase studies or products

market; iTeos may not be able to fulfill its business plans

to implement, including compliance with the expected or planned

Regulatory, research and clinical milestones and timelines

development plans and the market launch of its product candidates

various reasons, some of which are beyond the control of iTeos

including possible financial and other restrictions

Company resources, manufacturing limitations, the

may not be able to be foreseen or remedied in a timely manner,

negative developments in the field of immuno-oncology, such as: b.

adverse events or disappointing results, including related to

Therapies from competitors and decisions from regulatory authorities and courts

or authorities, such as B. U.S. Patent and Trademark Office Decisions Regarding

to patents covering our product candidates; and the risks involved

under the heading “Risk Factors” in iTeos’ Quarterly Report on Form 10-Q

for the quarter ended September 30, 2023, which is included

filed with the Securities and Exchange Commission (SEC), as well as in others

The company’s SEC filings you should take note of.

We caution investors not to place undue reliance on anything contained in this press release

any forward-looking statements contained herein. iTeos doesn’t cover any

Obligation to publicly update its forward-looking statements,

unless required by law.

For further information please contact:

Investor contact:

Carl Mauch

iTeos Therapeutics, Inc.

[email protected]

See also  The realization of the great rejuvenation of the Chinese nation has entered an irreversible historical process

Media contact:

[email protected]


You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy